NgR3 Inhibitors
Chemical inhibitors of NgR3 can function through various indirect mechanisms by acting on different components of the neural signaling pathways with which NgR3 interacts. LY341495, as a potent and selective antagonist of metabotropic glutamate receptors, can lead to the functional inhibition of NgR3 by blocking mGluRs, thus altering the downstream signaling that intersects with NgR3's function in neurons. Likewise, MPEP's selective antagonism of mGluR5 impacts synaptic plasticity and neuronal signaling in a way that inhibits the functional activity of NgR3. D-Cycloserine's action on NMDA receptors changes the dynamics of synaptic transmission and neural plasticity, indirectly leading to the inhibition of NgR3. Similarly, Phencyclidine and Ifenprodil, by inhibiting NMDA receptors, disrupt the associated neuronal pathways and can therefore inhibit NgR3 function.
Natural and synthetic compounds alike can influence the inhibitory control of NgR3 through their action on neural signaling. Magnesium, through its role as a natural NMDA receptor antagonist, and Memantine, a synthetic non-competitive NMDA receptor antagonist, both inhibit the receptor's activity, thus impacting pathways in which NgR3 is active. Riluzole, which modulates glutamatergic neurotransmission, can lead to the functional inhibition of NgR3 by influencing glutamate signaling. Minocycline, by inhibiting microglial activation, can indirectly inhibit NgR3, considering microglia's influence on neuronal signaling. Methotrexate inhibits the release of glutamate, thereby reducing the excitatory drive within neural circuits that NgR3 is a part of, resulting in functional inhibition. Kynurenic acid, through its antagonistic effect on the glycine site of the NMDA receptor, alters the receptor's activity and consequently inhibits NgR3. PPADS, by inhibiting purinergic P2X receptors, can disrupt the signaling pathways and thus inhibit NgR3 function, due to the receptors' involvement in neural transmission.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 341495 | 201943-63-7 | sc-361244 sc-361244A | 1 mg 10 mg | $89.00 $223.00 | 1 | |
LY341495 is a potent and selective antagonist of metabotropic glutamate receptors (mGluRs). NgR3, involved in neuronal growth inhibition, can be functionally inhibited by the blockade of mGluRs because these receptors modulate neuronal signaling pathways that intersect with NgR3 functions. LY341495, by inhibiting mGluRs, can thus indirectly lead to the inhibition of NgR3. | ||||||
D-Cycloserine | 68-41-7 | sc-221470 sc-221470A sc-221470B sc-221470C | 200 mg 1 g 5 g 25 g | $28.00 $77.00 $142.00 $530.00 | 4 | |
D-Cycloserine is a partial agonist at the glycine modulatory site of the NMDA receptor. NMDA receptors are crucial in neural plasticity and signaling pathways that NgR3 is also involved in. D-Cycloserine's action on NMDA receptors can indirectly inhibit NgR3 by modulating the neural pathways associated with the protein. | ||||||
Ifenprodil hemitartrate | 23210-58-4 | sc-203601B sc-203601 sc-203601A | 5 mg 10 mg 50 mg | $39.00 $61.00 $142.00 | ||
Ifenprodil is a selective NMDA receptor antagonist that targets the NR2B subunit. It can indirectly inhibit NgR3 by modulating NMDA receptor activity, which in turn influences the neuronal pathways where NgR3 functions. | ||||||
Riluzole | 1744-22-5 | sc-201081 sc-201081A sc-201081B sc-201081C | 20 mg 100 mg 1 g 25 g | $20.00 $193.00 $213.00 $317.00 | 1 | |
Riluzole is a drug that modulates glutamatergic neurotransmission. It can indirectly inhibit NgR3 by influencing glutamate signaling, which is a part of the pathway NgR3 is known to influence in neuronal cells. | ||||||
Minocycline, Hydrochloride | 13614-98-7 | sc-203339 sc-203339A sc-203339B sc-203339C sc-203339D sc-203339E sc-203339F | 50 mg 250 mg 1 g 2.5 g 10 g 100 g 1 kg | $52.00 $171.00 $281.00 $634.00 $1259.00 $5836.00 $24980.00 | 36 | |
Minocycline is a tetracycline antibiotic that has been found to inhibit microglial activation. As microglia can affect neuronal signaling and plasticity, minocycline's inhibition of microglia can indirectly influence NgR3 activity in neurons, leading to its functional inhibition. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate, primarily known for its use in cancer and autoimmune diseases, has been shown to inhibit the release of glutamate. By reducing glutamate levels, methotrexate can indirectly inhibit NgR3 as glutamatergic signaling is part of the neural pathways involving NgR3. | ||||||
Kynurenic acid | 492-27-3 | sc-202683 sc-202683A sc-202683B | 250 mg 1 g 5 g | $26.00 $57.00 $138.00 | 6 | |
Kynurenic acid is an antagonist at the glycine site of the NMDA receptor and also at the α7 nicotinic acetylcholine receptor. As these receptors are part of the signaling pathways that NgR3 is involved in, kynurenic acid can indirectly inhibit NgR3 by modulating receptor activity. | ||||||
Memantine hydrochloride | 41100-52-1 | sc-203628 | 50 mg | $69.00 | 4 | |
Memantine is a non-competitive NMDA receptor antagonist that is known to inhibit NMDA receptor-mediated calcium influx. It can indirectly inhibit NgR3 function by affecting the NMDA receptor signaling pathways, which are associated with NgR3 activity in neural cells. | ||||||